These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31602763)

  • 21. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.
    Ofman JJ; Dorn GH; Fennerty MB; Fass R
    Aliment Pharmacol Ther; 2002 Feb; 16(2):261-73. PubMed ID: 11860409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
    Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
    Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients.
    Delcher A; Hily S; Boureau AS; Chapelet G; Berrut G; de Decker L
    PLoS One; 2015; 10(11):e0141779. PubMed ID: 26535585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of intravenous proton pump inhibitors in high-risk bleeders.
    van Zanten SV
    Can J Gastroenterol; 2004 Dec; 18(12):749-50. PubMed ID: 15605141
    [No Abstract]   [Full Text] [Related]  

  • 26. Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism.
    Swaminathan K
    Indian J Pharmacol; 2015; 47(3):330-1. PubMed ID: 26069375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: acid suppression in the management of gastro-oesophageal reflux disease--an appraisal of treatment options in primary care.
    Jones R; Bytzer P
    Aliment Pharmacol Ther; 2001 Jun; 15(6):765-72. PubMed ID: 11380314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Histamine
    Hammond DA; Kathe N; Shah A; Martin BC
    Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.
    Janssen MJ; Van Oijen AH; Verbeek AL; Jansen JB; De Boer WA
    Aliment Pharmacol Ther; 2001 May; 15(5):613-24. PubMed ID: 11328254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial.
    Krag M; Perner A; Wetterslev J; Wise MP; Borthwick M; Bendel S; Pelosi P; Keus F; Guttormsen AB; Schefold JC; Møller MH;
    Trials; 2016 Apr; 17(1):205. PubMed ID: 27093939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
    Dickman R; Schiff E; Holland A; Wright C; Sarela SR; Han B; Fass R
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1333-44. PubMed ID: 17875198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proton pump inhibitors as a treatment method for type II diabetes.
    Mefford IN; Wade EU
    Med Hypotheses; 2009 Jul; 73(1):29-32. PubMed ID: 19304401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
    Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
    PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.
    Calvet X; Gené E; López T; Gisbert JP
    Aliment Pharmacol Ther; 2001 Jul; 15(7):1067-76. PubMed ID: 11421884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of Proton Pump Inhibitor Deprescription Protocol in Geriatric Residents.
    Avraham O; Biglow M
    Ann Pharmacother; 2018 Aug; 52(8):747-753. PubMed ID: 29473423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice.
    Cooper AL; Langworthy H; Porter S
    Int J Clin Pract; 2000 Jun; 54(5):287-92. PubMed ID: 10954954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?
    Lee TJ; Fennerty MB; Howden CW
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1241-51. PubMed ID: 15606386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients.
    Siupsinskiene N; Adamonis K; Toohill RJ; Sereika R
    J Laryngol Otol; 2008 Nov; 122(11):1206-12. PubMed ID: 18331659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Vallve M; Vergara M; Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1149-56. PubMed ID: 12030958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
    Maléth J; Hegyi P
    Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.